LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Home・Aandelen Lijst・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Gesloten

SectorGezondheidszorg

203.7 -1.02

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

202.67

Max

208.63

Belangrijke statistieken
By Trading Economics
Inkomsten	56M -39M
Verkoop	57M 158M
Winstmarge	-24.585
Werknemers	1,017
EBITDA	51M 2.3M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+27.49% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	729M 12B
Vorige openingsprijs	204.72
Vorige sluitingsprijs	203.7

Nieuwssentiment

By Acuity

50%

160 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

157.66 / 167.29 Steun & Weerstand

Ascendis Pharma A-S ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 nov 2025, 17:45 UTC

Winsten

Belangrijke Marktbewegers

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 nov 2025, 17:31 UTC

Winsten

Belangrijke Marktbewegers

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

15 nov 2025, 18:03 UTC

Winsten

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- UPDATED -- WSJ

15 nov 2025, 15:43 UTC

Winsten

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- WSJ

15 nov 2025, 12:00 UTC

Winsten

Meta Opens Pop-Up Stores to Build Buzz for Its AI Glasses -- WSJ

15 nov 2025, 09:20 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

15 nov 2025, 09:20 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

15 nov 2025, 00:08 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14 nov 2025, 23:56 UTC

Acquisities, Fusies, Overnames

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 nov 2025, 23:02 UTC

Marktinformatie

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 nov 2025, 22:35 UTC

Winsten

Acquisities, Fusies, Overnames

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 nov 2025, 22:32 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 nov 2025, 22:29 UTC

Winsten

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 nov 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 nov 2025, 21:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

14 nov 2025, 21:18 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 nov 2025, 20:27 UTC

Marktinformatie

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 nov 2025, 20:23 UTC

Marktinformatie

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 nov 2025, 20:17 UTC

Acquisities, Fusies, Overnames

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 nov 2025, 19:29 UTC

Marktinformatie

Winsten

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 nov 2025, 18:44 UTC

Marktinformatie

Winsten

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 nov 2025, 18:27 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 nov 2025, 18:27 UTC

Marktinformatie

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 nov 2025, 18:20 UTC

Marktinformatie

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 nov 2025, 17:20 UTC

Marktinformatie

Winsten

Auto & Transport Roundup: Market Talk

14 nov 2025, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

14 nov 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

14 nov 2025, 16:51 UTC

Marktinformatie

Starbucks Gets Holiday Sales Lift -- Market Talk

14 nov 2025, 16:48 UTC

Marktinformatie

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14 nov 2025, 16:38 UTC

Marktinformatie

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

Peer Vergelijking

Prijswijziging

Ascendis Pharma A-S ADR Prognose

Koersdoel

By TipRanks

27.49% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 260.58 USD 27.49%

Hoogste 325 USD

Laagste 220 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ascendis Pharma A-S ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Gebaseerd op 13 analisten die aandelenratings hebben gegeven aan Ascendis Pharma A-S ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

157.66 / 167.29Steun & Weerstand

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

160 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.